TY - JOUR
T1 - Dietary selenium supplementation modifies breast tumor growth and metastasis
AU - Chen, Yu Chi
AU - Prabhu, K. Sandeep
AU - Das, Arunangshu
AU - Mastro, Andrea M.
PY - 2013/11/1
Y1 - 2013/11/1
N2 - The survival rate for breast cancer drops dramatically once the disease progresses to the metastatic stage. Selenium (Se) is an essential micronutrient credited with having high anticancer and chemopreventive properties. In our study, we investigated if dietary Se supplementation modified breast cancer development in vivo. Three diets supplemented with sodium selenite, methylseleninic acid (MSA) or selenomethionine (SeMet), as well as a Se-deficient and a Se-adequate diet were fed to mice before mammary gland inoculation of 4T1.2 cells. The primary tumor growth, the numbers of cancer cells present in lungs, hearts, livers, kidneys and femurs and several proinflammatory cytokines were measured. We found that inorganic selenite supplementation provided only short-term delay of tumor growth, whereas the two organic SeMet and MSA supplements provided more potent growth inhibition. These diets also affected cancer metastasis differently. Mice fed selenite developed the most extensive metastasis and had an increased incidence of kidney and bone metastasis. On the other hand, mice fed the SeMet diet showed the least amount of cancer growth at metastatic sites. The MSA diet also provided some protection against breast cancer metastasis although the effects were less significant than those of SeMet. The cytokine profiles indicated that serum levels of interlukin-2, interleukin-6, interferon γ and vascular endothelial growth factor were elevated in SeMet-supplemented mice. There was no significant difference in tumor growth and the patterns of metastasis between the Se-deficient and Se-adequate groups. Our data suggest that organic Se supplementation may reduce/delay breast cancer metastasis, while selenite may exacerbate it. What's new? While previous studies have suggested that selenium may possess anticancer and chemopreventative properties, whether its dietary intake has any effect on late stages of cancer, especially metastasis, is largely unknown. Here, comparison of different types of dietary selenium supplements in mice reveals that selenomethionine (SeMet), a form of the mineral used in foods, may reduce or delay breast cancer metastasis, whereas selenite, a form found in soil, may encourage the development of extensive metastases. The results shed light on the application of selenium in cancer treatment and research.
AB - The survival rate for breast cancer drops dramatically once the disease progresses to the metastatic stage. Selenium (Se) is an essential micronutrient credited with having high anticancer and chemopreventive properties. In our study, we investigated if dietary Se supplementation modified breast cancer development in vivo. Three diets supplemented with sodium selenite, methylseleninic acid (MSA) or selenomethionine (SeMet), as well as a Se-deficient and a Se-adequate diet were fed to mice before mammary gland inoculation of 4T1.2 cells. The primary tumor growth, the numbers of cancer cells present in lungs, hearts, livers, kidneys and femurs and several proinflammatory cytokines were measured. We found that inorganic selenite supplementation provided only short-term delay of tumor growth, whereas the two organic SeMet and MSA supplements provided more potent growth inhibition. These diets also affected cancer metastasis differently. Mice fed selenite developed the most extensive metastasis and had an increased incidence of kidney and bone metastasis. On the other hand, mice fed the SeMet diet showed the least amount of cancer growth at metastatic sites. The MSA diet also provided some protection against breast cancer metastasis although the effects were less significant than those of SeMet. The cytokine profiles indicated that serum levels of interlukin-2, interleukin-6, interferon γ and vascular endothelial growth factor were elevated in SeMet-supplemented mice. There was no significant difference in tumor growth and the patterns of metastasis between the Se-deficient and Se-adequate groups. Our data suggest that organic Se supplementation may reduce/delay breast cancer metastasis, while selenite may exacerbate it. What's new? While previous studies have suggested that selenium may possess anticancer and chemopreventative properties, whether its dietary intake has any effect on late stages of cancer, especially metastasis, is largely unknown. Here, comparison of different types of dietary selenium supplements in mice reveals that selenomethionine (SeMet), a form of the mineral used in foods, may reduce or delay breast cancer metastasis, whereas selenite, a form found in soil, may encourage the development of extensive metastases. The results shed light on the application of selenium in cancer treatment and research.
UR - http://www.scopus.com/inward/record.url?scp=84882719393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882719393&partnerID=8YFLogxK
U2 - 10.1002/ijc.28224
DO - 10.1002/ijc.28224
M3 - Article
C2 - 23613334
AN - SCOPUS:84882719393
VL - 133
SP - 2054
EP - 2064
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 9
ER -